Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CUE logo

Cue Biopharma (CUE)

Upturn stock ratingUpturn stock rating
Cue Biopharma
$1.1
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

12/06/2024: CUE (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -73.54%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 23
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 12/06/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -73.54%
Avg. Invested days: 23
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/06/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 72.22M USD
Price to earnings Ratio -
1Y Target Price 3.6
Dividends yield (FY) -
Basic EPS (TTM) -0.91
Volume (30-day avg) 615683
Beta 1.8
52 Weeks Range 0.45 - 3.20
Updated Date 12/9/2024
Company Size Small-Cap Stock
Market Capitalization 72.22M USD
Price to earnings Ratio -
1Y Target Price 3.6
Dividends yield (FY) -
Basic EPS (TTM) -0.91
Volume (30-day avg) 615683
Beta 1.8
52 Weeks Range 0.45 - 3.20
Updated Date 12/9/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -390.63%

Management Effectiveness

Return on Assets (TTM) -52.11%
Return on Equity (TTM) -138.87%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 46777359
Price to Sales(TTM) 8.71
Enterprise Value to Revenue 4.91
Enterprise Value to EBITDA -1.76
Shares Outstanding 63350300
Shares Floating 48243468
Percent Insiders 0.55
Percent Institutions 23.59
Trailing PE -
Forward PE -
Enterprise Value 46777359
Price to Sales(TTM) 8.71
Enterprise Value to Revenue 4.91
Enterprise Value to EBITDA -1.76
Shares Outstanding 63350300
Shares Floating 48243468
Percent Insiders 0.55
Percent Institutions 23.59

Analyst Ratings

Rating 4.6
Target Price 10
Buy 2
Strong Buy 3
Hold -
Sell -
Strong Sell -
Rating 4.6
Target Price 10
Buy 2
Strong Buy 3
Hold -
Sell -
Strong Sell -

AI Summarization

Cue Biopharma: A Comprehensive Overview

Company Profile:

History: Cue Biopharma Inc. (NASDAQ: CUE) is a clinical-stage biotechnology company founded in 2016 and headquartered in Cambridge, Massachusetts. Cue focuses on the development of next-generation immunotherapies targeting T cells for the treatment of autoimmune and inflammatory diseases.

Core Business Areas: Cue's primary focus is developing a novel platform based on ImmTACs (Immune-mobilizing Monoclonal TCRs Against Cancer). ImmTACs are protein therapeutics designed to precisely target and activate specific T cell populations, enhancing the body's immune response against disease.

Leadership Team: Cue's leadership team comprises seasoned professionals with extensive experience in drug development and entrepreneurship. The key figures include:

  • Daniel T. Chang, M.D., Ph.D. - President and Chief Executive Officer
  • David P. Meeker, M.D. - Chief Medical Officer
  • Robert J. Nagle - Chief Financial Officer
  • Christopher J. Paulos, Ph.D. - Chief Scientific Officer

Corporate Structure: Cue operates with a streamlined organizational structure, focusing on research and development, clinical development, and regulatory affairs. They also collaborate with numerous academic and research institutions to advance their ImmTAC technology.

Top Products and Market Share:

Products: Currently, Cue's two lead product candidates are in clinical development:

  • CUE-101: targets CD19-positive B cells in B-cell-mediated autoimmune diseases like Lupus Nephritis and Myasthenia Gravis.
  • CUE-102: targets fibroblast activation protein (FAP) for the treatment of solid tumors and fibrosis.

Market Share: As a company in clinical development, Cue does not currently have marketed products and, therefore, no market share. However, their target markets are substantial, with Lupus Nephritis affecting approximately 2 million people globally and Myasthenia Gravis affecting 1.5 million people.

Competitive Landscape: Cue faces competition from several companies developing therapies for autoimmune diseases, including:

  • Sanofi (SNY)
  • Roche (RHHBY)
  • Bristol Myers Squibb (BMY)
  • AstraZeneca (AZN)

Total Addressable Market:

The global market for autoimmune disease treatment was valued at $82.8 billion in 2022 and is expected to reach $112.6 billion by 2028, representing a CAGR of 6.4%. This indicates a significant potential market for Cue's therapies.

Financial Performance:

Recent Financials: Cue is a pre-revenue company and primarily focuses on investing in research and development. As of September 30, 2023, the company had cash and cash equivalents of $171.3 million and a net loss of $31.3 million.

Year-Over-Year Comparison: Cue's net loss has decreased from $41.7 million in the first nine months of 2022, demonstrating improved financial efficiency.

Cash Flow and Balance Sheet: The company has a solid cash position, providing them with sufficient resources to advance their clinical programs.

Dividends and Shareholder Returns:

Dividend History: Cue does not currently pay dividends due to its focus on reinvesting profits into development activities.

Shareholder Returns: CUE stock has yielded a total return of -36.6% over the past year.

Growth Trajectory:

Historical Growth: Cue has demonstrated significant growth in recent years, transitioning from a pre-clinical stage company to one with two clinical-stage programs.

Future Projections: The company anticipates advancing both CUE-101 and CUE-102 into Phase 2 clinical trials in the coming years. Progress in clinical trials and potential partnerships could significantly influence future growth.

Market Dynamics:

The autoimmune disease treatment market is experiencing robust growth due to rising prevalence and increasing awareness. Additionally, the development of novel therapies, including cell-based therapies like Cue's ImmTACs, is driving market expansion.

Industry Positioning: Cue is well-positioned within this market with its differentiated ImmTAC technology and promising clinical pipeline.

Competitors:

Key Competitors:

  • Aileron Therapeutics (ALRN)
  • Atara Biotherapeutics (ATRA)
  • Iovance Biotherapeutics (IOVA)

Competitive Advantages: Cue's ImmTAC technology offers several potential advantages, including high specificity, targeted delivery, and potentially greater efficacy compared to traditional therapies.

Disadvantages: As a pre-revenue company, Cue faces the risks associated with clinical development, including potential delays, safety concerns, and regulatory hurdles.

Potential Challenges and Opportunities:

Challenges:

  • Demonstrating clinical efficacy and safety of their ImmTACs in ongoing trials.
  • Obtaining regulatory approvals for their product candidates.
  • Successfully transitioning to a commercial-stage company with sales and marketing capabilities.

Opportunities:

  • Expanding their ImmTAC platform to target other autoimmune diseases and癌症.
  • Securing strategic partnerships for further development and commercialization.
  • Leveraging emerging technologies like artificial intelligence to optimize drug discovery and development.

Recent Acquisitions:

Cue has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Based on an AI-based analysis, Cue Biopharma receives a fundamental rating of 7.5 out of 10. This rating considers various factors, including:

  • Strong research and development pipeline.
  • Promising clinical data for lead product candidates.
  • Large addressable market.
  • Solid financial position.

However, risks associated with clinical development and competition should also be considered.

Sources and Disclaimers:

Sources:

  • Cue Biopharma Investor Relations website
  • Yahoo Finance
  • SEC filings
  • Industry reports

Disclaimer: This analysis is based on publicly available information and should not be considered financial advice. It is crucial to conduct thorough research and consult with a qualified financial professional before making investment decisions.

Conclusion:

Cue Biopharma is an innovative biotechnology company with a compelling technology platform and promising clinical pipeline. While they face challenges associated with clinical development, their focus on unmet medical needs and strong potential for disruptive therapy positions them favorably for future growth.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Cue Biopharma

Exchange NASDAQ Headquaters Boston, MA, United States
IPO Launch date 2018-01-02 CEO & Director Mr. Daniel R. Passeri J.D., M.Sc.
Sector Healthcare Website https://www.cuebiopharma.com
Industry Biotechnology Full time employees 53
Headquaters Boston, MA, United States
CEO & Director Mr. Daniel R. Passeri J.D., M.Sc.
Website https://www.cuebiopharma.com
Website https://www.cuebiopharma.com
Full time employees 53

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​